Anebulo Pharmaceuticals (NASDAQ:ANEB) Releases Earnings Results

Anebulo Pharmaceuticals (NASDAQ:ANEB) posted its earnings results on Friday. The company reported ($0.09) EPS for the quarter, Zacks reports.

Anebulo Pharmaceuticals Stock Performance

ANEB opened at $1.33 on Friday. The company has a fifty day moving average of $1.51 and a two-hundred day moving average of $1.73. The stock has a market capitalization of $34.49 million, a price-to-earnings ratio of -4.43 and a beta of -1.15. Anebulo Pharmaceuticals has a fifty-two week low of $0.80 and a fifty-two week high of $3.30.

Insider Transactions at Anebulo Pharmaceuticals

In other Anebulo Pharmaceuticals news, Director Aron R. English bought 10,101,010 shares of Anebulo Pharmaceuticals stock in a transaction dated Monday, December 23rd. The stock was acquired at an average cost of $0.99 per share, with a total value of $9,999,999.90. Following the purchase, the director now directly owns 15,467,300 shares in the company, valued at $15,312,627. This represents a 188.23 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 85.90% of the company’s stock.

Analysts Set New Price Targets

Separately, Benchmark restated a “speculative buy” rating and issued a $8.00 price objective on shares of Anebulo Pharmaceuticals in a research report on Tuesday, November 19th.

About Anebulo Pharmaceuticals

Anebulo Pharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI.